Form 4: Blueprint Medicines COO Christina Rossi Sells Shares Under 10b5-1 Trading Plan

Christina Rossi, Chief Operating Officer of Blueprint Medicines Corp, sold 2,274 shares of common stock at an average price of $95.02 on March 24, 2025, under a pre-arranged trading plan.

Summary

• On March 24, 2025, Christina Rossi, the Chief Operating Officer of Blueprint Medicines Corp, sold 2,274 shares of the company's common stock.
• The sale was executed at an average price of $95.02 per share.
• The transactions occurred within a price range of $95.00 to $95.06.
• The sale was conducted under a pre-arranged trading plan adopted on August 27, 2024, in accordance with Rule 10b5-1.
• Following the reported transaction, Rossi directly owns 69,266 shares of Blueprint Medicines Corp.
• The reporting person will provide full information regarding the number of shares sold at each separate price within the range set forth in this footnote upon request.

Sentiment

Score: 5

Explanation: The document is a routine regulatory filing related to an insider stock sale under a pre-arranged trading plan, suggesting a neutral sentiment.

Industry Context

Sales by corporate insiders are a common occurrence and are often pre-planned to avoid accusations of insider trading. Investors often monitor these sales for signals about the company's prospects, although they can be driven by personal financial planning needs.

Stakeholder Impact

• The stock sale may have a minor impact on shareholders, potentially creating slight downward pressure on the stock price in the short term.

Key Dates

Keywords

Form 4, Blueprint Medicines, BPMC, Christina Rossi, Chief Operating Officer, Stock Sale, 10b5-1 Trading Plan, Insider Trading